secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001651308-22-000208
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene Q3 product revenue up 82% to $349.5M; BRUKINSA sales +136%; net loss widens
--------------------------------------------------------------------------------

- Product revenue $349.5M (+82% YoY); BRUKINSA global sales $155.5M (+136%), U.S. $108.1M (+221%).
- Net loss $557.6M ($0.41/share) vs $438.1M loss prior year; includes $125.6M FX losses.
- Cash $5.1B (down from $6.6B); cash used in operations $561.9M.
- BRUKINSA achieved superior PFS vs ibrutinib in ALPINE final analysis; EC approved MZL; CHMP positive for CLL.
- Tislelizumab China sales $128.2M (+67%); HCC trial met OS endpoint vs sorafenib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130822000208/0001651308-22-000208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130822000208/bgne-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001651308-22-000208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer